Abstract: BACKGROUND: The causes for immune-mediated inflammatory diseases (IMIDs) are diverse and the incidence trends of IMIDs from specific causes are rarely studied. The study aims to investigate the pattern and trend of IMIDs from 1990 to 2019. METHODS: We collected detailed information on six major causes of IMIDs, including asthma, inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, psoriasis, and atopic dermatitis, between 1990 and 2019, derived from the Global Burden of Disease study in 2019. The average annual percent change (AAPC) in number of incidents and age standardized incidence rate (ASR) on IMIDs, by sex, age, region, and causes, were calculated to quantify the temporal trends. FINDINGS: In 2019, rheumatoid arthritis, atopic dermatitis, asthma, multiple sclerosis, psoriasis, inflammatory bowel disease accounted 1.59%, 36.17%, 54.71%, 0.09%, 6.84%, 0.60% of overall new IMIDs cases, respectively. The ASR of IMIDs showed substantial regional and global variation with the highest in High SDI region, High-income North America, and United States of America. Throughout human lifespan, the age distribution of incident cases from six IMIDs was quite different. Globally, incident cases of IMIDs increased with an AAPC of 0.68 and the ASR decreased with an AAPC of -0.34 from 1990 to 2019. The incident cases increased across six IMIDs, the ASR of rheumatoid arthritis increased (0.21, 95% CI 0.18, 0.25), while the ASR of asthma (AAPC = -0.41), inflammatory bowel disease (AAPC = -0.72), multiple sclerosis (AAPC = -0.26), psoriasis (AAPC = -0.77), and atopic dermatitis (AAPC = -0.15) decreased. The ASR of overall and six individual IMID increased with SDI at regional and global level. Countries with higher ASR in 1990 experienced a more rapid decrease in ASR. INTERPRETATION: The incidence patterns of IMIDs varied considerably across the world. Innovative prevention and integrative management strategy are urgently needed to mitigate the increasing ASR of rheumatoid arthritis and upsurging new cases of other five IMIDs, respectively. FUNDING: The Global Burden of Disease Study is funded by the Bill and Melinda Gates Foundation. The project funded by Scientific Research Fund of Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital (2022QN38).
Tags: Academy of Pharmacy as council member and bursar, outside the submitted work. K, Adept Field Solutions, Clinical Care Options, Clearview Healthcare Partners,, all outside, all outside the submitted work. A K Demetriades reports leadership or fiduciary, all outside the submitted work. C R Simpson reports research grants, and A Radfar report payment or honoraria for lectures, presentations, speakers, anti-pollution mask, A system and method for electricity generation through crop, as personal payments, bureaus, manuscript writing or educational events from Avicenna Medical and, Clinical Research Institute. T Fukumoto reports payment or honoraria for, Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis and, consulting fees, consulting fees from Crealta/Horizon, Medisys, Fidia, PK Med, Two Labs Inc.,, Department of Anthropology, Panjab University, Chandigarh, India, outside the, Digitalization, MCID, for project titled "Enhancing institutional performance, editor and director (unpaid), equipment (PPE) into biofuel through pyrolysis and method, A novel herbal, European Association of Neurosurgical Societies (EANS) as President and with, events from AbbVie, Eli Lilly, Sanofi, Pfizer, Maruho, Novartis, Taiho, Sun, fiduciary role in other board, society, committee or advocacy group, paid or, Foundation, Australian Department of Health to their institution, from MBIE (NZ), HRC (NZ), Ministry of Health (NZ), MRC (UK), HDRUK, and CSO (UK), from TARGET RWE, Global burden of disease study, Global Neuro Foundation as Board Member, all outside the submitted work. I Filip, Hub Health Germany as Founding Member and Co-manager, all outside the submitted, Immune-mediated inflammatory disease, Incidence, India, Member Secretary-DSTPURSE Program., interests as an employee of AstraZeneca, outside the submitted work. E Upadhyay, Kintara Therapeutics, Intelligent Biosolutions, Acumen Pharmaceutical, TPT Global, Krishan reports non-financial support from UGC Centre of Advanced Study, CAS II,, Labs, Pieris Pharmaceuticals, Enzolytics Inc., Seres Therapeutics, Tonix, leadership, leadship for Joint Secretary of Indian Meteorological Society, Jaipur Chapter,, lectures, presentations, speakers bureaus, manuscript writing or educational, licenses from UptoDate as personal payments for a chapter on plantar fasciitis, Life Science, UBM, Trio Health, Medscape, WebMD, Practice Point Communications,, OMERACT, or fiduciary role in board, society, committee or advocacy group, paid or unpaid,, other board, society, committee or advocacy group, unpaid, with the Malaysian, other financial interests from PRAHS/ICON PLC through, outside the submitted work. N Ismail reports leadership or fiduciary role in, outside the submitted work. S Bhaskar reports leadership or, owned stock options in Amarin, Viking, and Moderna Pharmaceuticals, payment or honoraria for speakers' bureaus from Simply, Pharma, UCB, and Janssen Pharma, all outside the submitted work. C Herteliu, pharmaceutical aid for formulation of gel and method thereof, and reports, Pharmaceuticals Holding Corp., and Charlotte's Web Holdings, Inc., and previously, Putnam Associates, Focus Forward, Navigant Consulting, Spherix, MedIQ, Jupiter, reports a published patent for A system and method of reusable filters for, reports a research grant from Romanian Ministry of Research Innovation and, Research Council (NHMRC), Arthritis Australia, Cabrini Foundation, HCF, restricted stock units, Rheumatology Field Advisory Committee as Chair (unpaid), and with the UAB, role in other board, society, committee or advocacy group, paid or unpaid, with, Rotary District 9675 as Chair of Diversity, Equity and Inclusion, and with Global, royalties or, SARS-CoV-2 preimmune epitopes, SNC to their institution, University of California San Francisco, Speaking, stock or stock options in Atai Life Sciences,, stock or stock options in ICON PLC through, stubble by using microbial fuel cells, A system for disposed personal protection, submitted work. V Shivarov reports a pending Bulgarian patent for Possible, support for attending meetings or travel from the steering committee of, Tech, Vaxart Pharmaceuticals, Atyu Biopharma, Adaptimmune Therapeutics, GeoVax, the National Institutes of Health, and the American College of Rheumatology all, the submitted work. M Zielinska reports other financial or non-financial, their salary, through development of infrastructure and transdisciplinary research ecosystem, to their institution, all outside the submitted work. J A Singh reports, Trend, unpaid participation on a Data Safety Monitoring Board or Advisory Board, unpaid, with the Rotary Club or Sydney as Board Director and Chair of Youth, with, with OMERACT as a steering committee member, with the Veterans Affairs, with the US Food and Drug Administration Arthritis Advisory Committee, within socio-economic domain-PERFECTIS," project number ID-585-CTR-42-PFE-2021,, work. R Buchbinder reports grants from Australian National Health and Medical.
RSS 2.0